IMMUNE PHARMACEUTICALS, INC.

(IMNPQ)
Delayed OTC Markets  -  05/20 09:30:19 am EDT
0.001000 USD    0.00%
2021IMMUNE PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Change in Directors or Principal Officers, Other Events (form 8-K)
AQ
2021IMMUNE PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events (form 8-K)
AQ
2020Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.

10/21/2019 | 12:00am EDT

The US Bankruptcy Court gave an order approving the sale of certain assets of Immune Pharmaceuticals, Inc on October 21, 2019. The debtor has been authorized to sell its certain assets to Alexion Pharmaceuticals, Inc., for a purchase price of $6 million in cash. The debtor’s assets include Anti-Eotaxin Assets. At the auction held, Alexion Pharmaceuticals, Inc. emerged as the winning bidder by offering a purchase price of $6 million.


© S&P Capital IQ 2019
All news about IMMUNE PHARMACEUTICALS, INC.
2021IMMUNE PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Change in..
AQ
2021IMMUNE PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events (form..
AQ
2020Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2020Motion For Case Conversion Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2019Immune Pharmaceuticals, Inc. cancelled the transaction announced on October 9, 2018
CI
2019Motion for Case Conversion or Dismissal Filed for Immune Pharmaceuticals, Inc.
CI
2019Bidding Procedure Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Filed by Immune Pharmaceuticals, Inc.
CI
2019Motion for Case Conversion Filed by Immune Pharmaceuticals, Inc.
CI
More news
Chart IMMUNE PHARMACEUTICALS, INC.
Duration : Period :
Immune Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Adeel Ahmed-Daudpota President & Chief Executive Officer
Devin J. Shaw Chief Financial Officer
John Zhang Vice President-Research & Development
John A. Neczesny Independent Director
Jeffrey Paley Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNE PHARMACEUTICALS, INC.-23.08%0
JOHNSON & JOHNSON3.45%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707